The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.
An article from
Gene editing
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.
Published July 6, 2026
Nasdaq MarketSite headquarters in New York, N.Y., on Aug. 21, 2022.
The biotech scorecard for the third quarter: 15 stock-moving events to watch
BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’
More signs that GLP-1s may help with peripheral artery disease
Eli Lilly just placed a $40 million bet on the next injectable boom | Fortune
A new gene-editing startup negotiated contracts with a Chinese company, raised $230 million in funding, and executed a…
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in…
Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans…
Two companies aiming to make better babies by tweaking the DNA of embryos were invited to talk about the future of the technology…
Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230…
